, /PRNewswire/ -- . (Canary), the leading AI-powered voice biomarker health tech company, has secured a Series A funding round led by Cortes Capital, LLC (Love's Private Equity), with participation from Sorenson Communications, LLC., SMK ( ), and Hackensack Meridian Health.
With robust patent positioning, Canary is at the forefront of the industry with nine issued patents protecting the use of vocal biomarkers in healthcare. Canary aims to expand its team to support the accelerating growth driven by advancements in artificial intelligence and the healthcare industry's demand for more advanced tools. As an API-first company, Canary's vocal biomarker technology has a wide range of applications within the healthcare industry.
These applications include contact centers, ambient clinical listening, remote patient monitoring, and annual wellness checks. Ambient listening tools, which are systems designed to unobtrusively capture and analyze conversations in real-time, enable healthcare providers to focus on patient interactions while automatically documenting clinical notes. "There are technologies that truly disrupt the way healthcare is administered, and Canary is committed to pioneering vocal biomarkers and ambient listening for the betterment of healthcare," said , co-founder and CEO of Canary Speech.
, as many as 85 percent of physicians may adopt ambient listening tools. Canary's vocal biomarker technology enhances these tools by adding real-time screening for behavioral and .
